The new contract will see Advogent continue to logistical services and technology support for B-MS sales force-driven promotional and marketing programmes. Further details have not been released.
Advogent president Blake DeSimone said: “Our relationship with Bristol-Myers Squibb has extended over ten years,” adding that “over that time we have seen the regulatory requirements of the industry evolve the services we deliver from a meeting planning operation to a cross functional discipline.”
The renewal fits with recent B-MS efforts to hive off non-core assets and focus on the creation of novel innovative medicines. Earlier this month for example, it sold its Indonesian unit as well as Japanese rights to certain products to Taisho Pharmaceutical.
